miRNA-150 downregulation promotes pertuzumab resistance in ovarian cancer cells via AKT activation

Archives of Gynecology and Obstetrics

Volumn 292, Issue 5, 2015, Pages 1109-1116

  Wuerkenbieke, Delinaer ^a   Wang, Jing ^a   Li, Yan ^a   Ma, Cailing ^a  

^a XINJIANG MEDICAL UNIVERSITY   (China)

Author keywords

Drug resistance; miR 150; Ovarian cancer; Pertuzumab

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MICRORNA; MICRORNA 150; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; ANTINEOPLASTIC AGENT; CHROMONE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; MORPHOLINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENE SILENCING; INTRACELLULAR SIGNALING; MOLECULAR DYNAMICS; OVARIAN CANCER CELL LINE; SKOV3 CELL LINE; SNU119 CELL LINE; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; GENETICS; HUMAN; METABOLISM; NEOPLASM; OVARY TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CHROMONES; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MORPHOLINES; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 84942982286     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-015-3742-x     Document Type: Article

References (29)

1. Siegel RL, Miller KD (2015) Jemal A (2015) Cancer statistics. CA Cancer J Clin 65(1):5–29. doi:10.3322/caac.21254
2. Lengyel E (2010) Ovarian cancer development and metastasis. Am J Pathol 177(3):1053–1064. doi:10.2353/ajpath.2010.100105
3. Yap TA, Carden CP, Kaye SB (2009) Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 9(3):167–181. doi:10.1038/nrc2583
4. Tuefferd M, Couturier J, Penault-Llorca F, Vincent-Salomon A, Broet P, Guastalla JP, Allouache D, Combe M, Weber B, Pujade-Lauraine E, Camilleri-Broet S (2007) HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS One 2(11):e1138. doi:10.1371/journal.pone.0001138
5. Baselga J, Swain SM (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9(7):463–475. doi:10.1038/nrc2656
6. Langdon SP, Faratian D, Nagumo Y, Mullen P, Harrison DJ (2010) Pertuzumab for the treatment of ovarian cancer. Exp Opin Biol Ther 10(7):1113–1120. doi:10.1517/14712598.2010.487062
7. Metzger-Filho O, Winer EP, Krop I (2013) Pertuzumab: optimizing HER2 blockade. Clin Cancer Res 19(20):5552–5556. doi:10.1158/1078-0432.ccr-13-0518
8. He L, Hannon GJ (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5(7):522–531. doi:10.1038/nrg1379
9. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6(11):857–866. doi:10.1038/nrc1997
10. He Y, Jiang X, Chen J (2014) The role of miR-150 in normal and malignant hematopoiesis. Oncogene 33(30):3887–3893. doi:10.1038/onc.2013.346
11. Warth SC, Hoefig KP, Hiekel A, Schallenberg S, Jovanovic K, Klein L, Kretschmer K, Ansel KM, Heissmeyer V (2015) Induced miR-99a expression represses Mtor cooperatively with miR-150 to promote regulatory T-cell differentiation. EMBO J. doi:10.15252/embj.201489589
12. Jin M, Yang Z, Ye W, Xu H, Hua X (2014) MicroRNA-150 predicts a favorable prognosis in patients with epithelial ovarian cancer, and inhibits cell invasion and metastasis by suppressing transcriptional repressor ZEB1. PLoS One 9(8):e103965. doi:10.1371/journal.pone.0103965
13. Mraz M, Chen L, Rassenti LZ, Ghia EM, Li H, Jepsen K, Smith EN, Messer K, Frazer KA, Kipps TJ (2014) miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1. Blood 124(1):84–95. doi:10.1182/blood-2013-09-527234
14. Valabrega G, Montemurro F, Aglietta M (2007) Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 18(6):977–984. doi:10.1093/annonc/mdl475
15. Faratian D, Zweemer AJM, Nagumo Y, Sims AH, Muir M, Dodds M, Mullen P, Um I, Kay C, Hasmann M, Harrison DJ, Langdon SP (2011) Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies. Clin Cancer Res 17(13):4451–4461. doi:10.1158/1078-0432.ccr-10-2461
16. Nakajima H, Mizuta N, Sakaguchi K, Fujiwara I, Yoshimori A, Magae J, Tanuma S (2010) Enhancement of paclitaxel-induced apoptosis in HER2-overexpressing human breast cancer cells by a pertuzumab mimetic peptide,HRAP. J Biosci Bioeng 110(2):250–253. doi:10.1016/j.jbiosc.2010.02.007
17. Yao E, Zhou W, Lee-Hoeflich ST, Truong T, Haverty PM, Eastham-Anderson J, Lewin-Koh N, Gunter B, Belvin M, Murray LJ, Friedman LS, Sliwkowski MX, Hoeflich KP (2009) Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin Cancer Res 15(12):4147–4156. doi:10.1158/1078-0432.ccr-08-2814
18. Gajria D, Chandarlapaty S (2011) HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther 11(2):263–275. doi:10.1586/era.10.226
19. Mullen P, Cameron DA, Hasmann M, Smyth JF, Langdon SP (2007) Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling. Mol Cancer Ther 6(1):93–100. doi:10.1158/1535-7163.mct-06-0401
20. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2(7):489–501. doi:10.1038/nrc839
21. Greer EL, Brunet A (2005) FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24(50):7410–7425. doi:10.1038/sj.onc.1209086
22. Wu Y, Shang X, Sarkissyan M, Slamon D, Vadgama JV (2010) FOXO1A is a target for HER2-overexpressing breast tumors. Cancer Res 70(13):5475–5485. doi:10.1158/0008-5472.can-10-0176
23. Nahta R, Esteva FJ (2006) Herceptin: mechanisms of action and resistance. Cancer Lett 232(2):123–138. doi:10.1016/j.canlet.2005.01.041
24. Moasser MM (2007) The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26(45):6469–6487. doi:10.1038/sj.onc.1210477
25. Davis R, Singh KP, Kurzrock R, Shankar S (2009) Sulforaphane inhibits angiogenesis through activation of FOXO transcription factors. Oncol Rep 22(6):1473–1478. doi:10.3892/or_00000589
26. Han J, Pan XY, Xu Y, Xiao Y, An Y, Tie L, Pan Y, Li XJ (2012) Curcumin induces autophagy to protect vascular endothelial cell survival from oxidative stress damage. Autophagy 8(5):812–825. doi:10.4161/auto.19471
27. Zhou J, Liao W, Yang J, Ma K, Li X, Wang Y, Wang D, Wang L, Zhang Y, Yin Y, Zhao Y, Zhu WG (2012) FOXO3 induces FOXO1-dependent autophagy by activating the AKT1 signaling pathway. Autophagy 8(12):1712–1723. doi:10.4161/auto.21830
28. Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9(8):550–562. doi:10.1038/nrc2664
29. Fruman DA, Rommel C (2014) PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discovery 13(2):140–156. doi:10.1038/nrd4204